SALT LAKE CITY, UT--(Marketwire - May 08, 2009) - Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today the official launch of its new comprehensive corporate web site -- www.cancer-therapeutics.com. The state-of-the-art site is designed to better communicate with its customers and shareholders. In addition it offers improved functionality and a more accessible visual design providing a higher level of service.
In addition, Chene Gardner, President and CEO of Cancer Therapeutics, Inc., announced the company is moving in a new direction away from the biotherapy sector which included the company offering clinical services such as a cryobank, tumor derived activated cells and vaccines. Now Cancer Therapeutics will seek to create a footprint as a biotechnology business incubator with a specific emphasis on disruptive treatments and nanotechnology.
Gardner added, “The new direction better positions the company to take advantage of the projected $78 billion spent annually on cancer therapies. We are committed to developing key partnerships with companies who are some of the foremost innovators in the area of cancer treatment.”
The new corporate web site is easy to navigate and provides one-click access to pages featuring the company’s partners and products along with information on a variety of cancer treatments it is involved in. It also features an investor relations page with updated news and contact information. “Many times the introduction of a company is initially done through a corporate web site so it’s crucial to provide prospective investors, strategic partners and customers with a superior online experience which exemplifies who you really are as a company -- we believe we have accomplished that with ours,” said Gardner. “The site reflects our dedication to continuously improving communication between Cancer Therapeutics and our customers and shareholders. We’ll continue to add new features to our site to make it the kind of destination that is easy to use and truly valuable.”
About Cancer Therapeutics, Inc.:
Cancer Therapeutics, Inc. is a biotechnology business incubator, with a specific emphasis on disruptive treatments and nanotechnology. It seeks out disruptive cancer research and technology opportunities to invest in, develop, and commercialize. The end result will be therapies, treatments, and pharmaceuticals targeted at more efficiently and effectively attacking cancer. CTI seeks partners to co-develop drugs in various stages in our pipeline.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words “estimate,” “anticipate,” “expect,” “believe,” and similar expressions are intended to be forward-looking statements.
Contact:
Investor Relations
David Donlin
Cervelle Group
Phone: 407-614-5959 ext. 223
